AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 1437426
Drug: Mailed poisoning
RxNorm normalized name: poison ivy extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mailed poisoning prevention packet (telephone stickers, coupon for syrup of ipecac, cabinet lock, checklist, pamphlets, cover letter)
Trial: 26946313
Drug: Intravenous ascorbic
RxNorm normalized name: ascorbate
DrugBank: Ascorbic acid (DB00126)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous ascorbic acid infusion (2g administered starting 30 minutes before anesthesia for 2 hours)
Trial: 26946313
Drug: Placebo (administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (administered starting 30 minutes before anesthesia for 2 hours)
Trial: 26946313
Drug: Intravenous ascorbic
RxNorm normalized name: ascorbate
DrugBank: Ascorbic acid (DB00126)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous ascorbic acid infusion
Trial: 24792937
Drug: Cephalexin, 500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cephalexin, 500 mg (every 6 hours for 7 days)
Trial: 24792937
Drug: Clindamycin, 300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clindamycin, 300 mg (every 6 hours for 7 days)
Trial: 15139775
Drug: ITF-1697 dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ITF-1697 dose 2 (loading dose 110 microg/kg i.v., infusion 1.0 microg/kg/min for 24 hours)
Trial: 15139775
Drug: ITF-1697 dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ITF-1697 dose 1 (loading dose 55 microg/kg i.v., infusion 0.5 microg/kg/min for 24 hours)
Trial: 9755357
Drug: Long-term maintenance
RxNorm normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Long-term maintenance treatment for recurrent unipolar major depression; specific intervention details not provided.
Trial: 9755357
Drug: Continuation treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuation treatment of major depression; specific intervention details not provided.
Trial: 7736899
Drug: Continuous infusion
RxNorm normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous infusion of glucose with model assessment (CIGMA)
Trial: 7736899
Drug: Hyperglycaemic clamp
RxNorm normalized name: CLAMP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hyperglycaemic clamp (10 mmol/l)
Trial: 169104
Drug: Aminosidin-polymyxin B
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aminosidin-polymyxin B combination
Trial: 31177183
Drug: GOP infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: GOP infusion
Trial: 27053635
Drug: Baseline MRI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Baseline MRI parameters (T2 lesion number, T1 and T2 lesion volumes, corpus callosum (CC), thalamic fraction)
Trial: 27053635
Drug: 12-month MRI
RxNorm normalized name: moth bean
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 12-month MRI parameters (Expanded Disability Status Scale (EDSS), number of new or enlarging T2 lesions, CC volume % change)
Trial: 25637266
Drug: Edivoxetine (EDX)
RxNorm normalized name: EDX-502
DrugBank: Edivoxetine (DB09184)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Edivoxetine (EDX) 6 mg or 9 mg once daily for 14 or 15 days
Trial: 25637266
Drug: Atomoxetine (ATX)
DrugBank: Atomoxetine (DB00289)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Atomoxetine (ATX) 80 mg once daily for 14 or 15 days
Trial: 24102571
Drug: Dexmedetomidine (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexmedetomidine (1 μg kg(‐1) over 10 minutes, followed by 0.4 μg kg(‐1)h(‐1) for 60 minutes)
Trial: 19332208
Drug: Average glucose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Average glucose > or =144 mg/dL (8 mmol/L)
Trial: 21797816
Drug: Rimonabant 40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rimonabant 40 mg
Trial: 21797816
Drug: Rimonabant (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rimonabant (20 or 40 mg)
Trial: 12730412
Drug: Betaine (6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Betaine (6 g daily for 6 weeks)
Trial: 12730412
Drug: Folic acid
RxNorm normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Folic acid (800 micro g daily for 6 weeks)
Trial: 12730412
Drug: Placebo (6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (6 g daily for 6 weeks)
Trial: 2285608
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy using Flutamide and LHRH agonist (or orchiectomy) for an average of 771 days (24‐2607 days)
Trial: 2285608
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy using Flutamide and LHRH agonist (or orchiectomy)
Trial: 2285608
Drug: Monotherapy (not
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monotherapy (not specified in detail)
Trial: 393731
Drug: 0.5 mg
RxNorm normalized name: biotin 0.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 mg nickel supplements given on Monday and Tuesday of each week for at least 1 month
Trial: 23905242
Drug: Modified group:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Modified group: preoperative intramuscular injection of 50 mg dolantin, venous injection of 2 ml physiological saline, 10 mg dexamethasone, 5 mg ephedrine
Trial: 23905242
Drug: Traditional group:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Traditional group: intramuscular injection of 10 mg diazepam prior to routine anesthesia
Trial: 18758699
Drug: Nebivolol (starting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nebivolol (starting dose 2.5 mg once daily for 6 weeks)
Trial: 18758699
Drug: Metoprolol (starting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metoprolol (starting dose 25 mg once daily for 6 weeks)
Trial: 16644608
Drug: timolol-latanoprost combination
RxNorm normalized name: latanoprost / timolol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: timolol-latanoprost combination
Trial: 29866467
Drug: Combination treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination treatment (solifenacin succinate 5mg plus mirabegron 50mg)
Trial: 20164553
Drug: Radiofrequency field
RxNorm normalized name: Field mushroom
DrugBank: Field mushroom (DB15605)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Radiofrequency field exposure (890-MHz GSM signal, specific absorption rate of 1.0 Watt/kg) for 30 minutes
Trial: 20164553
Drug: Use of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Use of oral snuff
Trial: 17662037
Drug: Active immunotherapy
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active immunotherapy with Alternaria alternata extract
Trial: 10561949
Drug: Tropisetron 5
RxNorm normalized name: tropisetron 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tropisetron 5 mg plus dexamethasone 8 mg i.v. on day 1 followed by tropisetron 5 mg p.o. plus dexamethasone 4 mg orally bid on day 2‐6 (group I)
Trial: 10561949
Drug: Tropisetron 5
RxNorm normalized name: tropisetron 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tropisetron 5 mg p.o. alone on day 2‐6 (group II)
Trial: 31744796
Drug: Cord blood
RxNorm normalized name: CORD BLOOD
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cord blood serum (CBS) eyedrops administered eight times/day for 1 month
Trial: 31744796
Drug: Peripheral adult
RxNorm normalized name: OC 8 Adult Acne
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Peripheral adult donor blood serum (PBS) eyedrops administered eight times/day for 1 month
Trial: 31744796
Drug: CBS treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CBS treatment
Trial: 24219189
Drug: Motor learning
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Motor learning program (goal-oriented stepping and walking, strength training, twice weekly for 1 hour for 12 weeks)
Trial: 24219189
Drug: Standard exercise
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard exercise program (endurance training by treadmill walking, strength training, twice weekly for 1 hour for 12 weeks)
Trial: 21209239
Drug: Fostamatinib (R788)
RxNorm normalized name: fostamatinib
DrugBank: Fostamatinib (DB12010)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Fostamatinib (R788) 100 mg orally, twice daily from days 4 to 8 and once daily on days 3 and 9.
Trial: 21209239
Drug: Matching placebo,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo, twice daily from days 4 to 8 and once daily on days 3 and 9.
Trial: 7939398
Drug: Cisapride (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cisapride (5 mg four times daily)
Trial: 7939398
Drug: Cimetidine (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cimetidine (200 mg four times daily)
Trial: 29254749
Drug: Oral rehydrating
RxNorm normalized name: terpin hydrate Oral Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral rehydrating fluids (GIII)
Trial: 24366750
Drug: 75 mg
RxNorm normalized name: talc 75 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 75 mg oseltamivir
Trial: 24366750
Drug: 150 mg
RxNorm normalized name: pectin 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150 mg oseltamivir
Trial: 24366750
Drug: Both doses
RxNorm normalized name: Bothrops atrox venom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both doses of oseltamivir (75 mg and 150 mg)
Trial: 24366750
Drug: Standard dosing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard dosing of oseltamivir
Trial: 20660039
Drug: Postoperative TSH
RxNorm normalized name: TSH-releasing hormone
DrugBank: Protirelin (DB09421)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Postoperative TSH suppression therapy (group A) with L-T(4) to keep serum TSH levels below 0.01 μU/ml
Trial: 16199249
Drug: Levofloxacin 750
RxNorm normalized name: levofloxacin 750 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levofloxacin 750 mg/d for 5 days
Trial: 15032259
Drug: 150 mg
RxNorm normalized name: pectin 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150 mg bupropion SR daily and PTC
Trial: 15032259
Drug: 150 mg
RxNorm normalized name: pectin 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150 mg bupropion SR daily and TM
Trial: 15032259
Drug: 300 mg
RxNorm normalized name: rutin 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 mg bupropion SR daily and PTC
Trial: 15032259
Drug: 300 mg
RxNorm normalized name: rutin 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 mg bupropion SR daily and TM
Trial: 15032259
Drug: 150 mg
RxNorm normalized name: pectin 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150 mg bupropion SR
Trial: 15032259
Drug: 300 mg
RxNorm normalized name: rutin 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 mg bupropion SR
Trial: 11054442
Drug: Ceftazidime (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ceftazidime (2 g every 8 hours)
Trial: 1577054
Drug: DuP-753 25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DuP-753 25 mg
Trial: 1577054
Drug: DuP-753 50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DuP-753 50 mg
Trial: 1577054
Drug: DuP-753 100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DuP-753 100 mg
Trial: 1577054
Drug: DuP-753 200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DuP-753 200 mg
Trial: 1577054
Drug: DuP-753 100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DuP-753 100 mg (multiple doses)
Trial: 3298069
Drug: High doses
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High doses of anti-lipid A
Trial: 26172395
Drug: N-acetylcysteine (NAC)
DrugBank: Acetylcysteine (DB06151)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: N-acetylcysteine (NAC) 1800 mg orally for 4 months
Trial: 16846541
Drug: Budesonide HFA
RxNorm normalized name: Budesonide
DrugBank: Budesonide (DB01222)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Budesonide HFA pMDI 200 mug twice daily
Trial: 16846541
Drug: Budesonide CFC
RxNorm normalized name: Budesonide
DrugBank: Budesonide (DB01222)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Budesonide CFC pMDI 200 mug twice daily
Trial: 16846541
Drug: Both budesonide
RxNorm normalized name: Budesonide
DrugBank: Budesonide (DB01222)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Both budesonide formulations (HFA and CFC)
Trial: 10465472
Drug: Endobronchial treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endobronchial treatment (brachytherapy, laser resection, or cryotherapy)
Trial: 7840053
Drug: Continuous intravenous
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous intravenous infusion of epoprostenol plus conventional therapy
Trial: 627191
Drug: 0.9% sodium
RxNorm normalized name: LMD with 0.9% Sodium Chloride
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.9% sodium chloride solution (physiological saline)
Trial: 22624834
Drug: Pause-dependent augmentation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pause-dependent augmentation of J waves during storms of VF
Trial: 22624834
Drug: Pause-dependent augmentation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pause-dependent augmentation of J waves after sudden R-R prolongation
Trial: 22624834
Drug: Pause-dependent augmentation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pause-dependent augmentation of J waves
Trial: 18524974
Drug: Iodixanol-270 (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iodixanol-270 (60 mL intravenous bolus)
Trial: 16632399
Drug: Concurrent chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concurrent chemotherapy (CT) with radiation therapy (RT) - mitoxantrone (12 mg/m2), 5-FU (500 mg/m2), cyclophosphamide (500 mg/m2), 6 cycles, first 3 cycles of CT with RT
Trial: 16632399
Drug: Sequential chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential chemotherapy (CT) followed by radiation therapy (RT) - mitoxantrone (12 mg/m2), 5-FU (500 mg/m2), cyclophosphamide (500 mg/m2), 6 cycles, RT started 3 to 5 weeks after the 6th cycle of CT
Trial: 10228604
Drug: Echinaforce (Echinacea
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Echinaforce (Echinacea purpurea-preparation from 95% herba and 5% radix)
Trial: 10228604
Drug: Special Echinacea
RxNorm normalized name: Echinacea
DrugBank: Echinacea (DB14240)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Special Echinacea purpurea radix preparation
Trial: 8904594
Drug: Nasal inhalation
RxNorm normalized name: Nasal Inhalant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nasal inhalation of cold dry air (‐4 degrees C)
Trial: 8904594
Drug: Nasal inhalation
RxNorm normalized name: Nasal Inhalant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nasal inhalation of cold dry air (‐10 degrees C)
Trial: 8904594
Drug: Nasal inhalation
RxNorm normalized name: Nasal Inhalant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nasal inhalation of dry air (0.3% RH)
Trial: 8904594
Drug: Nasal inhalation
RxNorm normalized name: Nasal Inhalant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nasal inhalation of moist room air (97% RH)
Trial: 8904594
Drug: Oral breathing
RxNorm normalized name: cetylpyridinium chloride Mouthwash [Breath-Away]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral breathing of cold dry air, dry air, or moist air
Trial: 8904594
Drug: Nasal anesthesia
RxNorm normalized name: Gelato Anesthetic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nasal anesthesia or inhalation of a cholinergic antagonist before cold air
Trial: 1930699
Drug: Acetaminophen 650
RxNorm normalized name: acetaminophen 650 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetaminophen 650 mg with codeine 60 mg
Trial: 29604620
Drug: Caricol®-Gastro (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caricol®-Gastro (20 g, taken twice per day for 30 days)
Trial: 18564687
Drug: Combined DTPw‐HBV/Hib
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined DTPw‐HBV/Hib vaccine administered at 1.5, 3, and 5 months after a birth dose of hepatitis B vaccine (HBV)
Trial: 12718838
Drug: Combined DTPw‐HBV/Hib
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined DTPw‐HBV/Hib vaccine
Trial: 15958628
Drug: Marimastat 5
RxNorm normalized name: Marimastat
DrugBank: Marimastat (DB00786)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Marimastat 5 mg
Trial: 15958628
Drug: Marimastat 20
RxNorm normalized name: Marimastat
DrugBank: Marimastat (DB00786)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Marimastat 20 mg
Trial: 15958628
Drug: Marimastat 40
RxNorm normalized name: Marimastat
DrugBank: Marimastat (DB00786)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Marimastat 40 mg
Trial: 15958628
Drug: Marimastat (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Marimastat (all doses)
Trial: 10501821
Drug: Ciprofloxacin (CPF)
RxNorm normalized name: Ciprofloxacin
DrugBank: Ciprofloxacin (DB00537)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ciprofloxacin (CPF) 600 mg t.i.d.
Trial: 30499486
Drug: Bioresonance therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bioresonance therapy (BRT)
Trial: 17628912
Drug: Betamethasone 0.6
RxNorm normalized name: betamethasone 0.6 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Betamethasone 0.6 mg/day (n=8) or methylprednisolone 4 mg/day (n=6), single daily oral dose at 11.00 PM for 30 days
Trial: 17628912
Drug: Betamethasone 0.3
RxNorm normalized name: betamethasone 0.3 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Betamethasone 0.3 mg, single daily dose at 11.00 PM for six months
Trial: 17628912
Drug: Post-treatment evaluation
RxNorm normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Post-treatment evaluation of 11 patients after therapy withdrawal
Trial: 16149685
Drug: Cisapride (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cisapride (10 mg, tid ac for 2 weeks)
Trial: 12115016
Drug: Nimesulide suspension
RxNorm normalized name: nimesulide Oral Suspension
DrugBank: Nimesulide (DB04743)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nimesulide suspension 1.5 mg/kg per dose
Trial: 7960533
Drug: ESWL monotherapy
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ESWL monotherapy
Trial: 7960533
Drug: ESWL+PCNL combined
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ESWL+PCNL combined therapy
Trial: 3149152
Drug: Diclofenac sodium
RxNorm normalized name: Diclofenac Sodium
DrugBank: Diclofenac (DB00586)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Diclofenac sodium (150 mg, 75 mg twice daily)
Trial: 3149152
Drug: Aspirin (3.6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin (3.6 g, 1.2 g three times daily)
Trial: 18567822
Drug: Fluoxetine (6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluoxetine (6 weeks administration)
Trial: 18567822
Drug: Placebo (6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (6 weeks administration)
Trial: 15811211
Drug: gatifloxacin 0.3%
RxNorm normalized name: GATIFLOXACIN 0.3% SOLN,OPH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: gatifloxacin 0.3% administered BID
Trial: 15811211
Drug: gatifloxacin 0.3%
RxNorm normalized name: GATIFLOXACIN 0.3% SOLN,OPH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: gatifloxacin 0.3% administered QID
Trial: 11919461
Drug: 2% lignocaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2% lignocaine hydrochloride gel administered over 10 seconds
Trial: 11919461
Drug: 2% lignocaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2% lignocaine hydrochloride gel administered over 2 seconds
Trial: 9120744
Drug: Curosurf (modified
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Curosurf (modified porcine surfactant) administered at birth (80 mg/ml; dose 20 mg/kg)
Trial: 9120744
Drug: Curosurf (modified
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Curosurf (modified porcine surfactant) administered at birth
Trial: 6841943
Drug: Proglumide (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Proglumide (50 mg/kg bolus, 50 mg/kg hour infusion, 100 mg/kg hour infusion, or combination)
Trial: 6841943
Drug: Cimetidine (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cimetidine (2 mg/kg I.V. followed by 2 mg/kg hour)
Trial: 24362907
Drug: 600 mg
RxNorm normalized name: mesna 600 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 600 mg alpha-lipoic acid (ALA) three times a day orally for 24 weeks
Trial: 17882685
Drug: New low‐
FDA approved: no
EMA approved: no
PMDA approved: no
Description: New low‐ and ultra‐low‐dose oral preparations (0.3 mg conjugated equine estrogens and 0.5 mg estradiol)
Trial: 17882685
Drug: 14 microg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 14 microg transdermal system
Trial: 17882685
Drug: New progestogens
FDA approved: no
EMA approved: no
PMDA approved: no
Description: New progestogens (e.g. drospirenone, bioidentical progesterone, selective progesterone receptor modulators)
Trial: 17882685
Drug: New female
FDA approved: no
EMA approved: no
PMDA approved: no
Description: New female androgen patch
Trial: 17882685
Drug: Selective estrogen
RxNorm normalized name: Selective estrogen receptor modulator
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Selective estrogen receptor modulator/conjugated equine estrogen preparation combination
Trial: 15083368
Drug: HRT with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HRT with 0.625 mg oestrogen/day and 0.15 mg norgestrel